Ghana's public health agency partners with Chinese firm for AI-driven transformation
During the launch of the upcoming China-West Africa Medical and Health Industry Expo, Samuel Kaba Akoriyea, director-general of the Ghana Health Service (GHS), said that the collaboration with the Chinese company seeks to transform Ghana into a sub-regional hub for medical innovation and regional health advancement.
"Through this collaboration, we aim to establish AI treatment centers across Ghana, deploy AI-powered medical imaging and diagnosis systems in key healthcare facilities, and equip public and private hospitals, laboratories, and diagnostic centers with cutting-edge medical technologies," Akoriyea said.
Akoriyea said Ghana would also set up a cancer treatment and research center to serve national needs and expand access to modern surgical equipment, pharmaceutical solutions, and medical training resources through public-private partnerships.
About the upcoming expo, jointly presented by GHS and HCOWA, Akoriyea said this year's edition would attract over 1,500 stakeholders from across West Africa, more than 100 Chinese medical enterprises, and delegations from the public sectors in all 15 West African countries.
HCOWA Vice President Prince Opoku Dogbey said an AI medical supply chain platform, a digital platform, would be launched during the expo to enable foreign and local companies to trade medical supplies, forecast needs, and manage inventories with speed and precision, with Ghana as the pilot country.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
8 hours ago
- The Sun
Malaysia leads global medical device regulatory reliance with China
KUALA LUMPUR: Malaysia has achieved a major milestone in global healthcare regulation with the launch of the Medical Device Regulatory Reliance Programme in partnership with China. The initiative, led by the Medical Device Authority Malaysia (MDA), marks a strategic leap in streamlining approvals for medical devices between the two nations. MDA chief executive Dr P. Muralitharan stated that the programme allows mutual recognition of pre-market approvals, significantly reducing processing times. Malaysian in-vitro diagnostic (IVD) devices will now qualify for China's Green Channel, while Chinese devices can utilise Malaysia's Verification Pathway, cutting approval periods to 60 and 30 working days, respectively. 'This collaboration eliminates regulatory duplication, speeds up market entry, and ensures faster patient access to advanced medical technologies,' Muralitharan said. 'It also solidifies Malaysia's reputation as a regional regulatory leader and boosts investor trust in our healthcare ecosystem.' The programme was unveiled at the Healthcare Information and Management Systems Society Asia-Pacific (HIMSS APAC) Health Conference & Exhibition 2025, following a memorandum of understanding signed between MDA and China's National Medical Products Administration (NMPA) in November 2023. Muralitharan encouraged industry players to engage with MDA for further details, emphasising the programme's role in fostering efficient and transparent healthcare regulation. The initiative officially begins on July 30, reinforcing Malaysia's commitment to global health innovation. - Bernama
Barnama
9 hours ago
- Barnama
Malaysia Takes Global Lead In Medical Device Regulatory Reliance
KUALA LUMPUR, July 17 (Bernama) -- Malaysia has made historic advancement in international regulatory collaboration with the launch of the Medical Device Regulatory Reliance Programme between the country and China. Medical Device Authority Malaysia (MDA) chief executive Dr P. Muralitharan said the initiative represents a strategic breakthrough in accelerating access to safe and innovative medical technologies while reinforcing Malaysia's position as a global regulatory leader. He said the programme enables both countries to recognise each other's regulatory decisions for pre-market approvals, with Malaysian IVD devices now qualifying for China's Green Channel, while Chinese devices may use Malaysia's Verification Pathway, reducing approval timelines to 60 and 30 working days, respectively.
The Sun
10 hours ago
- The Sun
ASEAN calls for regional cooperation to lower HIV drug costs
KUCHING: ASEAN must develop a regional approach to address the high cost of antiretroviral (ARV) drugs for HIV treatment, said Deputy Health Minister Datuk Lukanisman Awang Sauni. He emphasised the importance of these medications in sustaining successful HIV treatment programmes. 'We must collectively explore strategies to secure better pricing, voluntary licensing, and regional procurement solutions. We must move forward not in isolation, but as a unified region,' he said during the opening of the ASEAN Regional Dialogue on Affordable ARV Drugs and Promoting Community-Based Testing (CBT) for Key Populations. Currently, the average annual cost of ARV treatment in Malaysia is around RM500. However, the country is shifting to a more advanced drug, Tenofovir-Lamivudine-Dolutegravir (TLD), which costs RM200 per month. 'The new TLD costs approximately RM200 per month, but our goal is to reduce it to at least RM100 per month. Although it is more expensive than the previous ARV, it is significantly more effective in treating patients,' Lukanisman explained. - Bernama
